Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IPSS Risk Category Intermediate-1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT00867061
What this trial is testing

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT01422486
What this trial is testing

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome (MDS)
Telik 2
Large-scale testing (Phase 3)UnknownNCT05024877
What this trial is testing

Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia

Who this might be right for
MDS
Peking Union Medical College Hospital 50
Very early researchLooking for participantsNCT06414681
What this trial is testing

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Who this might be right for
Myelofibrosis，MF
University of Kansas Medical Center 20
Testing effectiveness (Phase 2)Study completedNCT01048034
What this trial is testing

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic Leukemia
Nordic MDS Group 30
Testing effectiveness (Phase 2)Ended earlyNCT02599649
What this trial is testing

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 10
Testing effectiveness (Phase 2)Study completedNCT01584531
What this trial is testing

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromeMDSTrisomy 8
Traws Pharma, Inc. 82
Testing effectiveness (Phase 2)UnknownNCT03094637
What this trial is testing

Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
High Risk Myelodysplastic SyndromeIPSS Risk Category Intermediate-1Myelodysplastic Syndrome
M.D. Anderson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT03337451
What this trial is testing

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Opsona Therapeutics Ltd. 14
Early research (Phase 1)Study completedNCT03573310
What this trial is testing

JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Who this might be right for
NeoplasmsSolid Tumor, AdultNon-Hodgkin Lymphoma+1 more
Janssen Research & Development, LLC 114
Early research (Phase 1)Looking for participantsNCT07469891
What this trial is testing

PRT12396 in Participants With Select Myeloproliferative Neoplasms

Who this might be right for
Polycythemia Vera (PV)Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)+3 more
Prelude Therapeutics Incorporated 100
Testing effectiveness (Phase 2)Ended earlyNCT00467610
What this trial is testing

Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

Who this might be right for
Myelodysplastic Syndrome
Rush University Medical Center 6
Large-scale testing (Phase 3)Ended earlyNCT00804050
What this trial is testing

Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

Who this might be right for
Myelodysplastic Syndromes
Fondazione Italiana Sindromi Mielodisplastiche-ETS 184
Testing effectiveness (Phase 2)Study completedNCT00700206
What this trial is testing

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome (MDS)
Telik 86
Large-scale testing (Phase 3)Active Not RecruitingNCT02598661
What this trial is testing

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndromes
Geron Corporation 289
Not applicableStudy completedNCT02279654
What this trial is testing

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

Who this might be right for
Myelodysplastic Syndrome
Celgene 389
Testing effectiveness (Phase 2)Study completedNCT00806598
What this trial is testing

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic SyndromeAplastic Anemia
M.D. Anderson Cancer Center 53
Early research (Phase 1)Study completedNCT01895842
What this trial is testing

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Study completedNCT03011034
What this trial is testing

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Who this might be right for
Myelodysplastic Syndromes
Janssen Research & Development, LLC 34
Early research (Phase 1)Ended earlyNCT01362036
What this trial is testing

Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia

Who this might be right for
Myelodysplastic Syndrome (MDS)
Tarix Pharmaceuticals 2
Next Page